Eisenmenger Syndrome (ES) is a complex and severe form of pulmonary arterial hypertension associated with congenital heart defects, leading to significant morbidity and mortality. Traditional treatment options for ES are limited and often provide only symptomatic relief. Inhaled nitric oxide (iNO) has emerged as a promising therapeutic intervention due to its potent vasodilatory effects and ability to selectively target the pulmonary vasculature. This review explores the current understanding of the pathophysiology of ES, the pharmacodynamics of iNO, and the latest clinical evidence supporting its use. We examine the mechanisms by which iNO improves hemodynamics, oxygenation, and exercise capacity in patients with ES. Additionally, we discuss the practical considerations, potential adverse effects, and future directions for research in this evolving field. Our analysis suggests that iNO offers a significant therapeutic benefit, potentially improving quality of life and clinical outcomes for patients with Eisenmenger Syndrome.

Eisenmenger Syndrome, Pulmonary Arterial Hypertension, Inhaled Nitric Oxide

Steudel W, Hurford E. WE, Zapol WM (1999) Inhaled nitric oxide:Basic biology and clinical applications. Anesthesiology 91(4):1090–121.

Anas M, Triastuti N, Airlangga MP (2020) Role of Inhaled Nitric Oxides In Pregnancy With Eisenmenger Syndrome. Qanun Med J Fac Med Muhammadiyah Surabaya 4(1):11–26.

Anggard E (1994)Nitric Oxide: mediator, murderer, and medicine. Lancet 343:1199–206.

Atz AM, Wessel DL (1997) Inhaled nitric oxide in the neonate with cardiac disease. Semin Perinatol 21(5):441–55.

Galiè, N., Manes, A., & Branzi, A. (2004). The endothelin system in pulmonary arterial hypertension. Cardiovascular Research, 61(2), 227-237. doi:10.1016/j.cardiores.2003.10.011

Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., ... & Souza, R. (2019). Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 53(1), 1801913.

Diller, G. P., & Gatzoulis, M. A. (2007). Pulmonary vascular disease in adults with congenital heart disease. Circulation, 115(8), 1039-1050.

Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M., Bonnet, D., Fleming, T. R., ... & Raj, J. U. (2013). Pediatric pulmonary hypertension. Journal of the American College of Cardiology, 62(25 Supplement), D117-D126.

Macchia, A., Marchioli, R., Marfisi, R., Genser, B., Tavazzi, L., Tognoni, G., & Bavry, A. A. (2007). A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. American Heart Journal, 153(6), 1037-1047.

Adatia, I., & Haworth, S. G. (2002). Pulmonary hypertension in congenital heart disease. Cardiology in the Young, 12(3), 168-174.

Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, R., ... & Wilkins, M. R. (2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104(4), 424-428.

Rosenzweig, E. B., Kerstein, D., & Barst, R. J. (2001). Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation, 103(10), 2014-2016.

Moledina, S., Hislop, A. A., Foster, H., Chan, M., & Haworth, S. G. (2010). Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart, 96(17), 1401-1406.

Sitbon, O., Humbert, M., Jaïs, X., Ioos, V., Hamid, A. M., Provencher, S., ... & Simonneau, G. (2005). Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 111(23), 3105-3111.